PD 156707

Drug Profile

PD 156707

Alternative Names: CI 1020

Latest Information Update: 07 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Anti-ischaemics; Antihypertensives; Dioxoles
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cerebral ischaemia; Heart failure; Myocardial ischaemia; Pulmonary hypertension

Most Recent Events

  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
  • 09 Feb 1999 Data have been added to the Neurological disorder, Vascular disorder and Heart failure pharmacodynamics sections
  • 09 Feb 1999 Preclinical development for Congestive heart failure in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top